Sydney Stern, PhD’s Post

TL;DR: 1st levothyroxine MIPD for use in primary care suggests higher accuracy than conventional age or weight-based methods (using retrospective data + clinical simluation trials) American Society for Clinical Pharmacology & Therapeutics: ➡ https://bit.ly/3Vurpgu | #ModelInformedPrecisionDosing #MIPD #PresicionMedicine #PrecisionDosing #Levothyroxine

A new study demonstrates that the selection of an appropriate adult reference population is important for pediatric PK exposure matching and pediatric dose selection, especially for a drug that is substantially eliminated through renal excretion. The findings are useful for the extrapolation of the efficacy of other drugs from adult to pediatric populations. Published in CPT: Pharmacometrics & Systems Pharmacology. https://hubs.ly/Q02_CTkK0 | #PK #Pharmacokinetics #PopPK #Pharmacodynamics

Article no: 3 Excited to share the publication of my 3rd article in the "National Journal of Pharmacology and Therapeutics (NJPT). This research focuses on prescription patterns in post-COVID-19 mucormycosis patients, offering important insights for enhancing treatment strategies. #Pharmacology #Mucormycosis #COVID19 #DrugTherapy #ClinicalPharmacology #Therapeutics #PrescriptionPatterns #Pharmacotherapy #DrugSafety #PharmaceuticalResearch #ClinicalTrials #MedicinalChemistry #HealthcareResearch #DrugDevelopment

Despite PGx testing being instituted into standard clinical workflows, genotype-guided recommendations are not being adopted by all prescribers during treatment. To change standard of care, professional society clinical practice guidelines would need to endorse these recommendations; however, there has been hesitancy to do so without prospective randomized controlled trial data. How do we demonstrate evidence for implementation in cases where randomized controlled trials are not practical? Published in Clinical Pharmacology & Therapeutics. https://hubs.ly/Q02QDLqb0 | #PrecisionMedicine #PGx #Pharmacogenomics #Pharmacology Indiana University School of Medicine

Want to learn about estimands and why they are relevant in clinical pharmacology trials? Check out this new white paper from our experts - The Kangaroo, the Eagle and Why Estimands are Relevant.

"Optimizing Biologic Therapies: Pharmacometrics and Clinical Pharmacology Perspectives on Alternative Dosing Strategies" starts in just 1 hour (12 pm ET). Find out more about the significance of weight-based dosing and weight-related changes in exposure: https://bit.ly/4c14M94

This study investigated the most influential covariate (CYP2C19 phenotype) on exposure metrics for mavacamten to develop a population PK model to create an echocardiographic-based dose titration regimen. Published in CPT: Pharmacometrics & Systems Pharmacology. https://hubs.ly/Q02Pb0r90 | #Mavacamten #Pharmacokinetics #PrecisionMedicine #PharmacokineticModeling

"Beta blockers drug interactions" - In this slide I choose only the most important interactions with the most common drugs used by elderly patients - About omega-3 interaction, usually beta blockers (especially non-selective agents) increase the level of triglycerides (TG) in the blood, and omega-3 used to decrease its level. So using both agents together leading to decrease effect of omega-3 in decreasing TG, due to that natural products is not strong as chemical one in their affinity Wish you all the best! References: - Katzung's basic & clinical pharmacology, 16th edition  - BNF 86 #beta_blockers_interactions #CCB #omega_3 #insulin #clinical_pharmacology_30 #pharmacy_review #counseling_points #patient_education

Did you know that if you attend the Clinical Trials preconference at #ASCPT2024 you can learn case studies where clinical pharmacology practices have resulted in increased enrollment in subsequent trials: https://bit.ly/2rTP1zy

Three Clinical Pharmacology program Qs to ask: 1.  Is your clinical pharmacology program able to optimize patient recruitment? 2.  Have you fully characterized your product’s DDI liability (as a victim and perpetrator) and pharmacokinetic PK constraints? 3.  Are you maximizing your patient data by recruiting the right population?   RRD’s Clinical Pharmacology & Pharmacometrics Team can optimize trial performance and study outcomes. Contact us to start the conversation: info@rrdbiodev.com.